

OPEN ACCESS

APPROVED BY

Frontiers Editorial Office, Frontiers Media SA, Lausanne, Switzerland

*CORRESPONDENCE Bing Yang

[†]These authors have contributed equally to this work and share first authorship

RECEIVED 01 October 2025 ACCEPTED 02 October 2025 PUBLISHED 10 October 2025

CITATION

Wang X, Zhou Y, Li Q, Wang J, Qian Y and Yang B (2025) Correction: Case Report: Prognostic evaluation of immunotherapy in two patients with SMARCA4-UT using TCR as a new marker. *Front. Immunol.* 16:1717357. doi: 10.3389/fimmu.2025.1717357

COPYRIGHT

© 2025 Wang, Zhou, Li, Wang, Qian and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Correction: Case Report: Prognostic evaluation of immunotherapy in two patients with SMARCA4-UT using TCR as a new marker

Xiayu Wang^{1†}, Yiwei Zhou^{2†}, Qijiao Li², Jun Wang¹, Yu Qian¹ and Bing Yang^{1*}

¹Dept. of Thoracic Oncology, Hubei Cancer Hospital, Wuhan, China, ²Kindstar Global Precision Medicine Institute, Wuhan, China

KEYWORDS

SMARCA4, TCR, lung cancer, non-small cell lung carcinoma, check-point inhibitors, TILs

A Correction on

Case Report: Prognostic evaluation of immunotherapy in two patients with SMARCA4-UT using TCR as a new marker

By Wang X, Zhou Y, Li Q, Wang J, Qian Y and Yang B (2025). Front. Immunol. 16:1618118. doi: 10.3389/fimmu.2025.1618118

A correction has been made to the author list. The "equal contributions symbol" was erroneously excluded from authors "Xiayu Wang and Yiwei Zhou". The department for affiliation 2 has also been removed.

The corrected author list and affiliation appears below:

- "Xiayu Wang ^{‡1}, Yiwei Zhou ^{‡2}, Qijiao Li², Jun Wang¹, Yu Qian¹, Bing Yang¹*
- ¹Dept. of Thoracic Oncology, Hubei Cancer Hospital, Wuhan, China
- ²Kindstar Global Precision Medicine Institute, Wuhan, China
- [‡]These authors contributed equally to this work and share first authorship".

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.